Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
Journal of Clinical Oncology · 2026
DOI: 10.1200/jco-26-01135 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Rana R McKay und 25 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, La Jolla, CA. Hauptthemen laut MEDLINE: Anilides, Bone Neoplasms, Pyridines, Carcinoma, Renal Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223 ) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS This phase II trial enrolled patients with mRCC of any histology with ≥1 BM. Patients were randomly assigned 1:1 to cabozantinib ± radium-223, stratified by osteoclast-targeted therapy (OTT), prior therapy, opioid use, and International mRCC Database Consortium (IMDC) risk. The primary end point was SSE-free survival (SSE-FS). Secondary end points included safety, objective response rate (ORR), progression-free survival, and overall survival (OS). A target of 124 evaluable patients was planned, with a prespecified interim futility analysis at 50% of expected SSE-FS events; the trial would stop if the stratified hazard ratio (sHR) > 1.0. RESULTS The prespecified interim futility analysis was conducted after 90 patients were enrolled and crossed the futility boundary, leading to closure at 98 patients. The final analysis included all 98 patients. Median age was 63 years, 82.7% had clear cell histology, and 79.6% were using an OTT. IMDC risk was favorable (18.4%), intermediate (67.3%), and poor (14.3%). Median follow-up was 13.1 months. Median SSE-FS for cabozantinib with radium-223 versus cabozantinib was 16.7 versus 17.6 months (sHR, 1.46 [90% CI, 0.86 to 2.51]). Median OS was 28.3 versus 19.7 months (sHR, 1.40 [95% CI, 0.70 to 2.79]). ORR was 19.4% versus 25.0% ( P = .78). Grade ≥3 adverse events were similar across arms (69.6% v 75.5%). CONCLUSION Radium-223 did not improve SSE-FS when added to cabozantinib. The combination demonstrated a manageable safety profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California San Diego, La Jolla, CA.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN.
- IHA Hematology Oncology at St. Joe's Ann Arbor, Ypsilanti, MI.
- Springfield Clinic, Springfield, IL.
- Dana-Farber Cancer Institute, Boston, MA.
- Alliance Protocol Operations Office, University of Chicago, Chicago, IL.
ORCID-Profile: Rana R McKay, Karla V Ballman, Tareq Al Baghdadi, Brian C Baumann, Himisha Beltran, Stephanie Berg, Ronald C Chen, Atish D Choudhury, Suzanne Cole, Heather A Jacene, Joshua M Lang, Deepak Kilari, Young Kwok, Bradley McGregor, Michael J Morris, Mamta Parikh, Umang Swami, Alan Tan, Yuanquan A Yang, Tian Zhang, Matthew Galsky, Jonathan Rosenberg, Daniel George, Toni K Choueiri
Förderung
- NCI NIH HHS
Zitieren
APA
McKay, R. R., Ballman, K. V., Atherton, P. J., Ajmera, A., Al Baghdadi, T., Baumann, B. C., Beltran, H., Berg, S., Chen, R. C., Choudhury, A. D., Cole, S., Jacene, H. A., Lang, J. M., Kilari, D., Kwok, Y., McGregor, B., Morris, M. J., Parikh, M., Swami, U., …, & Choueiri, T. K. (2026). Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01135
Vancouver
McKay RR, Ballman KV, Atherton PJ, Ajmera A, Al Baghdadi T, Baumann BC, et al. Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801). Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01135
BibTeX
@article{McKay2026,
author = {McKay, Rana R and Ballman, Karla V and Atherton, Pamela J and Ajmera, Archana and Al Baghdadi, Tareq and Baumann, Brian C and Beltran, Himisha and Berg, Stephanie and Chen, Ronald C and Choudhury, Atish D and Cole, Suzanne and Jacene, Heather A and Lang, Joshua M and Kilari, Deepak and Kwok, Young and McGregor, Bradley and Morris, Michael J and Parikh, Mamta and Swami, Umang and Tan, Alan and Yang, Yuanquan A and Zhang, Tian and Galsky, Matthew and Rosenberg, Jonathan and George, Daniel and Choueiri, Toni K},
title = {Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)},
journal = {Journal of Clinical Oncology},
year = {2026},
doi = {10.1200/jco-26-01135}
}
EUVIMED